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Very low solubility in water and oils (<10 µg/ml) of DK-I-56-1 (7-methoxy-2-(4-methoxy-d3-
phenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3-one), the new drug candidate from the 
group of deuterated pyrazoloquinolinones [1], was the reason for investigation of nano-
crystalline suspensions (nanosuspensions) as prospective carriers. Nanosuspensions are 
dispersions of nanocrystals with submicron size stabilized by different surfactants and/or 
polymeric stabilizers [2]. In this research, formulation and comprehensive characterisation of 
DK-I-56-1 nanosuspensions were carried out. Nanosuspensions stabilized by polysorbate 80 
alone or in combination with poloxamer 188, poloxamer 407 or d-α-Tocopheryl polyethylene 
glycol 1000 succinate were prepared by small scale media milling technique. All formulations 
had particle size 208.7 – 250.6 nm, polydispersity index <0.250 and zeta potential around -20 
mV, and were stable for three weeks. According to thermal and X-ray diffraction analysis DK-
I-56-1 remained in crystalline state in all samples. Results from biodistribution studies in mice 
after intraperitoneal administration showed high plasma DK-I-56-1 levels after 
nanosuspension administration (AUC values for nanosuspension, suspension and solution: 
6770.35±770.69; 966.01±58.10; 10228.58±1037.23 ngh/ml, respectively). Brain availability 
was higher after nanosuspension compared to solution, while concentration profile after 
suspension showed bimodal characteristics. In in vivo behavioural (spontaneous locomotor 
activity) tests hyperlocomotion was observed after nanosuspension administration compared 
to saline or placebo (F(2,31)=7.126, p<0.01), while placebo was not behaviourally active 
compared to saline (p=0.289). In conclusion, DK-I-56-1 nanosuspensions with short term 
stability could be prepared and should be investigated as promising carrier for preclinical 
investigation.   
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